Sugi Predict

Sugi Predict / Compounds / SCHEMBL39934

SCHEMBL39934

SCHEMBL39934

CC(C)(C)OC(=O)NCCN1CCOCC1

nearest known ligand 0.60

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ CD274 Q9NZQ7 1/20 0.60
▸ TDP1 Q9NUW8 1/20 0.56
▸ DRD2 P14416 2/20 0.53
▸ CACNA1H O95180 1/20 0.52
▸ LMNA P02545 2/20 0.51
▸ TSHR P16473 2/20 0.50
▸ POLB P06746 2/20 0.49
▸ SMN1; SMN2 Q16637 1/20 0.49
▸ CA12 O43570 1/20 0.47
▸ CA1 P00915 1/20 0.47
▸ CA2 P00918 1/20 0.47
▸ CA9 Q16790 1/20 0.47
▸ MAPT P10636 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4753694 0.92 CD274 (0.54) CD274TDP1DRD2CACNA1HLMNA
SCHEMBL9093109 0.91 CD274 (0.53) CD274TDP1DRD2CACNA1HLMNA
SCHEMBL39968 0.91 LMNA (0.58) CD274DRD2LMNA
SCHEMBL4755773 0.90 CD274 (0.55) CD274TDP1DRD2CACNA1HLMNA
SCHEMBL2850188 0.89 CD274 (0.51) CD274TDP1DRD2LMNA
SCHEMBL31301242 0.89 DRD2 (0.63) CD274TDP1DRD2CACNA1H
SCHEMBL24172673 0.85 DRD2 (0.56) CD274TDP1DRD2CACNA1HCA12
SCHEMBL4024516 0.85 DRD2 (0.56) TDP1DRD2CACNA1HCA12CA1
SCHEMBL31301250 0.85 DRD2 (0.56) CD274TDP1DRD2CACNA1HCA12
SCHEMBL13202614 0.84 DRD2 (0.59) CD274TDP1DRD2CACNA1H

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 146 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4281463-A1 RAPAMYCIN ANALOGS AND USES THEREOF JANSSEN Pharmaceutica NV (BE) 2023-11-29 — — EP disclosed
US-20230357347-A1 MODULATORS OF G-PROTEIN COUPLED RECEPTORS CARMOT THERAPEUTICS, INC. 2023-11-09 — — US disclosed
EP-4272825-A2 MTORC MODULATORS AND USES THEREOF Aeovian Pharmaceuticals, Inc. (US) 2023-11-08 — — EP disclosed
CN-110922437-B Glucose compound, pharmaceutical composition and application thereof 凯惠科技发展(上海)有限公司 2023-11-03 — — CN disclosed
CN-116917294-A Rapamycin analogues and uses thereof 詹森药业有限公司 2023-10-20 — — CN disclosed
EP-3640248-B1 AMINOPYRIMIDINE DERIVATIVES, PREPARATION METHOD THEREFOR AND USE THEREOF BEIJING ADAMADLE BIOTECHNOLOGY LLC (CN) 2023-08-23 — — EP disclosed
EP-3601297-B9 COMPOUNDS THAT INHIBIT MCL-1 PROTEIN AMGEN INC (US) 2023-05-24 — — EP disclosed
EP-3601297-B9 COMPOUNDS THAT INHIBIT MCL-1 PROTEIN AMGEN INC (US) 2023-05-24 — — EP disclosed
CN-110691784-B Compounds for inhibiting MCL-1 protein 美国安进公司 2023-03-31 — — CN disclosed
US-20230028221-A1 EED INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF JING MEDICINE TECHNOLOGY (SHANGHAI) LTD. (CN) 2023-01-26 — — US disclosed
WO-2012006473-A1 COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT ARDELYX, INC. (US) 2012-01-12 — — WO disclosed
US-8088805-B2 Inhibitors of histone deacetylase METHYLGENE INC. (CA) 2012-01-03 — — US disclosed
US-8088805-B2 Inhibitors of histone deacetylase METHYLGENE INC. (CA) 2012-01-03 — — US disclosed
US-8022205-B2 Pyrimidine derivatives as PI3K inhibitor and use thereof CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2011-09-20 — — US disclosed
US-20100069629-A1 PYRIMIDINE DERIVATIVES AS PI3K INHIBITOR AND USE THEREOF CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2010-03-18 — — US disclosed
EP-2050749-A1 PYRIMIDINE DERIVATIVE AS PI3K INHIBITOR AND USE THEREOF CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2009-04-22 — — EP disclosed
US-20080132500-A1 Antibiotic compounds MERCK SHARP & DOHME CORP. 2008-06-05 — — US disclosed
US-20070213330-A1 Anticancer agents; antiproliferative agents METHYLGENE INC. (CA) 2007-09-13 — — US disclosed
US-20070213330-A1 Anticancer agents; antiproliferative agents METHYLGENE INC. (CA) 2007-09-13 — — US disclosed
US-7253204-B2 Antiproliferative agents METHYLGENE INC. (CA) 2007-08-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230357347-A1 MODULATORS OF G-PROTEIN COUPLED RECEPTORS GIPR, GLP1R, GCGR CD274 1889/4885TDP1 3206/4885DRD2 914/4885
US-20070213330-A1 Anticancer agents; antiproliferative agents HDAC1, HDAC11, HDAC5 CD274 2065/4885TDP1 701/4885DRD2 4733/4885
US-20100069629-A1 PYRIMIDINE DERIVATIVES AS PI3K INHIBITOR AND USE THEREOF PIK3CA, AKT3, AKT1 CD274 1639/4885TDP1 446/4885DRD2 3654/4885
US-20230028221-A1 EED INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF CYP4F11, CYP4A11, HSD11B1 CD274 4153/4885TDP1 1798/4885DRD2 1564/4885
US-20080132500-A1 Antibiotic compounds NRDC, MRPL21, PEPD CD274 1455/4885TDP1 3280/4885DRD2 3835/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.